• About us
• Contact

Advertisement

Organisation › Details

Mérieux (Group)

With extensive experience in industrial biology, Institut Mérieux contributes to serving medicine and public health across the globe. For the fight against infectious diseases and cancer, it imagines and develops new approaches in the fields of diagnostics, immunotherapy, and food safety and nutrition. With its three business activities- bioMérieux, Transgene and Silliker-Institut Mérieux has the potential to provide answers to the new challenges of public health globally: personalized medicine and new therapies, infectious diseases and cancer, food safety and nutrition. bioMérieux, listed on NYSE Euronext Paris and 59% owned, is based in Marcy l'Etoile (France). World leader of in vitro diagnostics and industrial microbiological controls. Transgene: Based in Strasburg (France), this biotech company is 55% controlled and is listed on NYSE Euronext Paris. It develops immunotherapy products for the treatment of cancer and infectious diseases. www.transgene.fr Silliker is a privately-owned company, 86% controlled, based in Chicago (United States), encompassing a network of nearly 50 laboratories dedicated to improving food safety and nutrition. www.silliker.com Institut Mérieux employs nearly 10,000 people in the service of public health worldwide and generates net sales of over 1.4 billion Euros. *

 

	Start	1992-07-01 existent
	Industry	in vitro diagnostics (IVD)
	Industry 2	food analysis (food testing)
	Region	Lyon
	Country	France
	City	n. a. Lyon
		Address record changed: 2020-12-02
Basic data	Employees	G: 5,001 to 10,000 (2010-08-12)
	Currency	EUR
	Annual sales	1,400,000,000 (net sales (2009) 2009-12-31)
		* Document for »About Section«:
		Record changed: 2024-02-12

Advertisement

More documents for Mérieux (Group)

• [1] bioMérieux S.A.. (1/13/25). "Press Release: bioMérieux Strengthens Its Point of Care Presence with the Acquisition of the Immunoassay Start-up SpinChip". Marcy l’Étoile....
• [2] bioMérieux S.A.. (1/13/25). "Press Release: bioMérieux to Present at the 43rd Annual J.P. Morgan HealthCare Conference". Marcy l’Étoile....
• [3] Mérieux NutriSciences Corporation. (10/7/24). "Press Release: Mérieux NutriSciences Enters Agreement to Acquire Worldwide Food Testing Business of Bureau Veritas". Chicago, IL....
• [4] Deepull Diagnostics S.L.. (5/22/24). "Press Release: Deepull Appoints Didier Deltort to Its Board of Directors". Barcelona....
• [5] Transgene S.A.. (1/22/24). "Press Release: Transgene Further Strengthens Management Team with Appointment of James Wentworth as Chief Business Officer". Strasbourg....
• [6] bioMérieux S.A.. (10/19/23). "Press Release: bioMérieux Makes Strategic Investment in Oxford Nanopore". Oxford & Marcy-l’Etoile....
• [7] Oxford Biomedica plc. (9/20/23). "Press Release: Oxford Biomedica and Institut Mérieux Enter into Exclusive Negotiations with Respect to the Proposed Acquisition by Oxford Biomedica of ABL Europe". Oxford....
• [8] Transgene S.A.. (5/5/23). "Press Release: Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio". Strasbourg....
• [9] bioMérieux S.A.. (4/14/23). "Press Release: Oxford Nanopore and bioMérieux to Enter into a Strategic Partnership Agreement to Develop Innovative Infectious Disease Diagnostics". Oxford & Marcy-l’Etoile....
• [10] ABL Biomanufacutring. (3/27/23). "Press Release: ABL Appoints Stéphanie Colloud as General Manager and Chief Operating Officer to Lead European Activities". Lyon....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.